JP2020500161A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500161A5
JP2020500161A5 JP2019520882A JP2019520882A JP2020500161A5 JP 2020500161 A5 JP2020500161 A5 JP 2020500161A5 JP 2019520882 A JP2019520882 A JP 2019520882A JP 2019520882 A JP2019520882 A JP 2019520882A JP 2020500161 A5 JP2020500161 A5 JP 2020500161A5
Authority
JP
Japan
Prior art keywords
antibody
treatment
agent
seq
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520882A
Other languages
English (en)
Japanese (ja)
Other versions
JP7676109B2 (ja
JP2020500161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/076751 external-priority patent/WO2018073363A1/en
Publication of JP2020500161A publication Critical patent/JP2020500161A/ja
Publication of JP2020500161A5 publication Critical patent/JP2020500161A5/ja
Application granted granted Critical
Publication of JP7676109B2 publication Critical patent/JP7676109B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520882A 2016-10-21 2017-10-19 抗ｋｉｒ３ｄｌ２剤による処置 Active JP7676109B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410880P 2016-10-21 2016-10-21
US62/410,880 2016-10-21
PCT/EP2017/076751 WO2018073363A1 (en) 2016-10-21 2017-10-19 Treatment with anti-kir3dl2 agents

Publications (3)

Publication Number Publication Date
JP2020500161A JP2020500161A (ja) 2020-01-09
JP2020500161A5 true JP2020500161A5 (enExample) 2020-11-26
JP7676109B2 JP7676109B2 (ja) 2025-05-14

Family

ID=60268349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520882A Active JP7676109B2 (ja) 2016-10-21 2017-10-19 抗ｋｉｒ３ｄｌ２剤による処置

Country Status (8)

Country Link
US (3) US20190248895A1 (enExample)
EP (1) EP3529277A1 (enExample)
JP (1) JP7676109B2 (enExample)
KR (2) KR20230173745A (enExample)
CN (1) CN109863175A (enExample)
AU (1) AU2017345203B2 (enExample)
CA (1) CA3037851A1 (enExample)
WO (1) WO2018073363A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
DK3896088T3 (da) 2013-02-20 2025-09-29 Innate Pharma Behandling af perifert t-cellelymfom
EP3116908B1 (en) 2014-03-14 2019-06-26 Innate Pharma Humanized kir3dl2 antibodies
BR112021014236A2 (pt) * 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia
US20250388702A1 (en) * 2019-10-04 2025-12-25 Dana-Farber Cancer Institute, Inc. Anti-kir3dl3 antibodies and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU1922902A (en) 2000-12-18 2002-07-01 Inst Nat Sante Rech Med Novel means for the diagnosis and therapy of CTCL
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
WO2005105848A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2379598B1 (en) 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
CA2881764C (en) 2012-09-19 2022-08-16 Innate Pharma Kir3dl2 binding agents
RU2682449C2 (ru) * 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
WO2014125041A1 (en) 2013-02-14 2014-08-21 Innate Pharma Treatment of peripheral t cell lymphoma
DK3896088T3 (da) 2013-02-20 2025-09-29 Innate Pharma Behandling af perifert t-cellelymfom
EP3116908B1 (en) 2014-03-14 2019-06-26 Innate Pharma Humanized kir3dl2 antibodies
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins

Similar Documents

Publication Publication Date Title
Pento Monoclonal antibodies for the treatment of cancer
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
AU2007281684C1 (en) Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
JP2022515077A5 (enExample)
JP2020529469A5 (enExample)
CN108473578A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
JP2020518598A (ja) 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
WO2016201425A9 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP2020508317A5 (enExample)
JP2013542194A5 (enExample)
CN105263520A (zh) 包含抗cd38抗体和来那度胺的组合物
JP2015514110A5 (enExample)
KR20120083359A (ko) ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법
MXPA02001398A (es) Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
RU2014139552A (ru) Человеческие антитела к токсинам clostridium difficile
Schuster et al. Immunotherapy with the trifunctional anti‐CD 20 x anti‐CD 3 antibody FBTA 05 (Lymphomun) in paediatric high‐risk patients with recurrent CD 20‐positive B cell malignancies
RU2019104980A (ru) Анти-icos антитела
CN105992590A (zh) 靶定癌症的il-12免疫疗法
JP2018515513A (ja) 多発性骨髄腫（ｍｍ）の処置
JP2018515493A5 (enExample)
JP2019507128A (ja) イヌ抗ｃｄ２０抗体
KR20240052084A (ko) 조합 및 이의 용도
CN112004828B (zh) 头颈癌的治疗
JP2023510429A5 (enExample)
JP2018533569A5 (enExample)